updat outlin setup potenti nash launch
deliv solid financi result manag outlook focus
prepar oca launch nash ocaliva revenu beat
estim consensu full year pbc sale reflect
y/i growth provid meaning sourc fund support nash
launch forecast launch earli follow highli anticip fda ad
subsequ pdufa nash launch prepar continu
sale forc infrastructur buildout drive adj opex guidanc
question also certain competit life-cycl dynam plan
oca combo bezafibr potenti combo
pbc sale beat estim consensu
pbc sale reach high end guidanc
repres y/i growth expect soften pbc sale due
season lower anticip reflect demand growth drive
overal y/i growth estim pbc sale exhibit
nash launch prepar continu ahead pdufa plan
articul posit risk/benefit oca fda ad context
larg unmet need payor discuss focu potenti reimburs
popul advanc fibrosi patient highest risk cirrhosi progress
expect label indic drive price exhibit
non-invas test nit diagnos crucial success nash launch
focus fibrosi highlight labcorp new code test
score plu liver panel cbc exampl evolv innov
salesforc reach specialist target educ
effort ahead launch mani specialist alreadi use nit nash diagnosi
treatment monitor exhibit
competit dynam continu inform long-term life-cycl manag plan
revers studi compensated-cirrhot patient complet
enrol data expect believ aldafermin
data show fibrosi improv increment valid fxr-agonist
moa suspect posit gnft elafibranor readout expect
would read-across posit oca bezafibr combin studi
believ signific first-mov advantag opportun
defin nascent nash market term leverag benefit oca
optim commerci potenti cash balanc provid strong
posit ahead launch updat model reflect actual
adj opex guidanc lower pt exhibit
year price histori
compani focus develop
novel treatment liver diseas
analyst certif import disclosur see disclosur
believ lead asset obetichol acid oca
approv treatment primari biliari cholang pbc
late-stag develop treatment nonalcohol
steatohepat nash addit indic well-
defin clinic benefit overal risk/reward profil
appear highli favor expect oca like becom
first-in-class treatment nash
pbc sale slightli consensu
fda adcomm vote favor oca nash
fda adcomm oca nash
nash approv launch
 specul driven nash competit dynam
investor becom comfort risk/reward around nash
pbc sale robust consensu
ocaliva launch slower anticip and/or reimburs low
oca fail gain fda approv nash
pt base dcf valuat wacc termin valu growth rate
risk includ clinic trial risk pivot us phase nash trial studi competit risk commerci risk pbc
sale fail meet expect
exhibit pbc sale beat estim consensu
expect soften pbc sale due season lower anticip reflect
demand growth drive overal y/i growth estim pbc sale
exhibit payor discuss focu potenti reimburs popul advanc fibrosi
patient highest risk cirrhosi progress expect label indic
exhibit plan initi target popul nash patient advanc fibrosi
without cirrhosi treat hepatologist gastroenterologist
exhibit non-invas test nit diagnos crucial success nash launch focus
fibrosi labcorp new code test plu liver panel cbc
exhibit cash balanc provid strong posit ahead launch
exhibit lower pt base dcf valuat methodolog
intercept dcfdiscount analysi except per-shar data mn except per-shar data revenu growth chang work work capit valu growth valu oppenheim co equiti valu per sharetermin valu growth rate intercept
probabl success
probabl success
probabl success
licens revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op
depreci exclud non-gaap op ex
interest dividend incom
revalu warrant
gaap ep basic dilut
laboratori corp hold america nyse lh cover
